The growing prevalence of movement disorders in India, coupled with the inability of many patients to access appropriate surgical intervention, has resulted in a substantial treatment gap. Against this backdrop, the deep brain stimulators (DBS) market in India is projected to witness an anticipated compound annual growth rate (CAGR) of over 10% through 2033, forecasts GlobalData, a leading data, and analytics company.

GlobalData’s report, “Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033,” reveals that India’s rechargeable deep brain stimulators market accounts for around 8% of the Asia-Pacific market in 2024, strengthened by a rising patient base, cost advantages, skilled neurosurgeons, and expanding healthcare infrastructure.

Medtronic Plc has recently introduced the Percept PC Deep Brain Stimulation system, the smallest and thinnest dual-channel neurostimulator for DBS. Equipped with BrainSense technology, it records and analyses brain signals in real time, enabling personalized treatments for conditions such as Parkinson’s disease, essential tremor, dystonia, and epilepsy.

Divya Soni, Medical Devices Analyst at GlobalData, comments: “As global life expectancy rises, age-related neurodegenerative disorders are becoming more prevalent. DBS systems have emerged as a treatment for these conditions but is limited by a battery life of 3-5 years, requiring periodic surgical replacement for non-rechargeable models, thus increasing patient burden and surgical risks.”

The Percept PC DBS system offers a rechargeable battery with over 15 years of service life, rapid charging, and future software update support, enhancing functionality without requiring device replacement. Additionally, as the only DBS system offering full-body MR Conditional compatibility, it ensures safe MRI scans with active bipolar stimulation under specific conditions, addressing the needs of most DBS patients.

Soni concludes: “While DBS devices serve as an effective treatment option for patients with movement disorders, they present notable shortcomings. The introduction of advanced DBS technologies offers a transformative solution in providing personalized, data-driven therapy, setting new standards in precision care, and improving quality of life across the country.”